Relmada Therapeutics, Inc. · NASDAQ:RLMD
Relmada Therapeutics — Investor Presentation (May 2015)
28 slides from Relmada Therapeutics's investor presentation, May 22, 2015
Slide 1: Relmada Therapeutics: Innovations in Pain Medicine
RELMADA THERAPEUTICS Innovations in Pain Medicine™ May 2015 Ticker Symbol OTCQB:RLMD
Slide 2: Forward Looking Statements
Forward Looking Statements Certain statements contained in this presentation or in other documents of Relmada Therapeutics (the “Company”), along with certain statements that may be made by management of the Company orally in presenting this material, may contain “forward- looking statements.” These
Slide 3: Company Highlights
a aa a ev? RELMADA Company Highlights e Robust portfolio of four drugs in development that address unmet needs in the largest drug prescription market in the world: the treatment of pain e Three products combine proven drug candidates with novel delivery methods to create new drugs with new indicati
Slide 4: Experienced Senior Management
RELMADA Experienced Senior Management An impressive track record developing and commercializing successful drugs Sergio Traversa, PharmD Chief Executive Officer Douglas Beck, CPA Chief Financial Officer Michael Becker Senior VP, Finance & Corp Dev Richard Mangano, Ph.D. Senior VP, Clinical Dev Lisa
Slide 5: Scientific Advisors
RELMADA Scientific Advisors Internationally recognized expertise from world-class scientific advisors Memorial loan Kettering Imperial College a JOHNS HOPKINS Cancer Center. London Gavril Pasternak, MD, PhD Andrew Rice, MD, FRCA Eric C. Strain, MD + Anne Bumatt Tandy Chain Neurology + Professor of P
Slide 6: Pain: Largest U.S. Public Health Crisis
Pain: Largest U.S. Public Health Crisis Prevalence 100M: Persistent Pain Annual Healthcare & Productivity Cost: $560-630 Billion’ 80M? © Cardiovascular Disease Annual Healthcare & Productivity 334 Million Cost: $309 Billion’ Prescriptions illi 29M2 © cancer and $13 Billion ‘Annual Healthcare & Produ
Slide 7: Portfolio Covers Entire Chronic Pain Spectrum
et RELMADA Portfolio Covers Entire Chronic Pain Spectrum Products in Market 2013 Sales ($M) Relmada Product Candidates Kadian®** Avinza® Severe Opana®** Nucynta® OxyContin® Vicodin@* i REL-1028 Ultram@* Moderate BuTrans® Suboxone® d-Methadone REL-1017 Lyrica® Cymbalta® Gabapentino* MepiGel REL-1021
Slide 8: Robust Product Portfolio
ot RELMADA d-Methadone REL-1017 voCap ER REL-1015 MepiGel Topical gol dosage form of REL-1021 Robust Product Portfolio Significant value creation possible in 12-24 months due to accelerated development timelines Pre-clinical Phase 1 Phase 2 Phase 3 Extended release, abuse resistant form of broad spe
Slide 9: d-Methadone
d-Methadone Novel NMDA antagonist for the treatment of neuropathic pain ee? RELMADA
Slide 10: d-Methadone — Benefits, Advantages, Features
a aa a et RELMADA d-Methadone — Benefits, Advantages, Features Neuropathic pain represents a large market opportunity ready for a new effective entry ¢ d-Methadone is a novel drug — Noncompetitive N-methyl-D-aspartate (NMDA) antagonist — Potential new treatment for estimated 5 million people sufferi
Slide 11: d-Methadone — Proof of Concept
a aa a et RELMADA d-Methadone — Proof of Concept ¢ Upregulation of NMDA plays important role in neuropathic pain * Inhibition of NMDA produces strong analgesia in neuropathic pain states — Example: low dose ketamine’ — Severe side effects limit use of ketamine + Psychedelic symptoms (hallucinations,
Slide 12: d-Methadone Next Steps
a aa a eo? RELMADA d-Methadone Next Steps Multiple development milestone potential in next 12-24 months Fas Daas |e | ° Cenpists Hizso | Start Phase II in * Complete Phase | multi dose study in 3 single dose study in ~20 patients . Se paren, II ~56 patients + FDAmeeting EB 5 interim results * Human
Slide 13: LevoCap ER
LevoCap ER Extended release, abuse resistant form of broad spectrum opioid levorphanol et RELMADA
Slide 14: LevoCap ER — Benefits, Advantages, Features
a aa a et RELMADA LevoCap ER - Benefits, Advantages, Features LevoCap ER will compete in the $8.5 billion opioid market if approved « LevoCap ER is an extended release, abuse deterrent formulation of levorphanol « Levorphanol is a unique, broad spectrum opioid with additional “non-opioid” mechanisms
Slide 15: Levorphanol's Broad Spectrum Activity
RELMADA Levorphanol’s Broad Spectrum Activity Levorphanol’s multi-modal mechanism of action provides for a more robust efficacy profile and potentially could be used alone for patients who take multiple drugs Opioid Mechanism Traditional Mu Opioid Receptors Delta Opioid Receptor Kappa Opioid Recepto
Slide 16: LevoCap ER Next Steps
LevoCap ER Next Steps Multiple development milestone potential in next 12-24 months * Obtain regulatory | ED, end of Phase approval from i . Il meeting * Continue Phase 3 Health Canada to Start Phase III start clinical trial * Pending feedback from FDA meeting 16
Slide 17: BuTab ER
BuTab ER First oral tablet form of buprenorphine for treating both pain and addiction
Slide 18: BuTab ER — Benefits, Advantages, Features
a aa a et RELMADA BuTab ER - Benefits, Advantages, Features The first form of buprenorphine in a tablet for use in pain and treating addiction + Buprenorphine is a partial opioid agonist with two indications: addiction and pain — More than $1.6 billion in annual revenue — Only schedule III opioid un
Slide 19: BuTab ER - Proof of Concept
SS et RELMADA BuTab ER - Proof of Concept 1. Positive single dose bioavailability of oral buprenorphine demonstrated in dogs 2. Inhibition of CYP3A4 enzyme with steroid budesonide — Poor oral drug bioavailability due to cytochrome P450 (CYP)- mediated first-pass metabolism + Sub-family enzyme CYP3A4
Slide 20: BuTab ER Next Steps
BuTab ER Next Steps Multiple development milestone potential in next 12-24 months ¥ Obtain regulatory approval from Health Canada to start clinical trial + Start Phase 1 in ~30 patients * Complete proof-of- concept Phase | NDA filing for opioid dependence Start Phase III for pain
Slide 21: MepiGel
MepiGel Topical gel dosage form of the local anesthetic mepivacaine for the treatment of neuropathic pain et RELMADA
Slide 22: MepiGel — Benefits, Advantages, Features
a aa a et RELMADA MepiGel — Benefits, Advantages, Features MepiGel will compete with Lidoderm® patch and its $948 million in peak sales if approved + MepiGel is the first topical gel dosage form of local anesthetic mepivacaine, which has intrinsic vasoconstrictor attributes — Reduces rate at which d
Slide 23: MepiGel Next Steps
MepiGel Next Steps Multiple development milestone potential in next 12-24 months * Human pain model + File Clinical Trial * Complete Phase! ° Proof-of-concept Application (CTA) in ~20 patients Phase II in +200 patients 2
Slide 24: Milestones & Commercial Opportunity
MILESTONES & COMMERCIAL OPPORTUNITY RELMADA
Slide 25: Near-term Value Drivers
REL Near-term Value Drivers Multiple development milestone potent months next 12-24 + Complete Phase | multi COUSUEG ICM - Complete Phase | single dose study REL-1017 dose study + FDAmeeting + Human pain model results + FDAend of Phase I TOTES | + Obtain regulatory approval ° FOP . REL-1015 to start
Slide 26: Commercial Opportunity
. et RELMADA Commercial Opportunity Multi-billion established markets for chronic pain therapy Products in Market 2013 Sales ($M) Relmada Product Candidates Kadian®** Avinza® Severe Opana®** Nucynta® OxyContin® Vicodin@* REL-1028 Ultram@* Suboxone® REL-1017 Moderate EEMEns) d-Methadone Lyrica® Cymba
Slide 27: Company Highlights
a aa a ev? RELMADA Company Highlights e Robust portfolio of four drugs in development that address unmet needs in the largest drug prescription market in the world: the treatment of pain e Three products combine proven drug candidates with novel delivery methods to create new drugs with new indicati
Slide 28: Relmada Therapeutics contact details
et RELMADA THERAPEUTICS Innovations in Pain Medicine™ 546 Fifth Ave 14th Floor New York, NY 10036 www.relmada.com Tel: (212) 702-7163 Email: info@relmada.com Ticker Symbol OTCQB:RLMD
Relmada Therapeutics — Investor Presentation (May 2015) on 6ix